LIMITED SUBMISSION: NCI – Cancer Prevention Clinical Trials Network (CP-CTNet): CP-CTNet Sites (UG1 Clinical Trial Required)

****PLEASE NOTE: ONE (1) PROPOSAL FROM TUFTS MAY BE NOMINATED****

DEADLINES:
Tufts Internal Email of Intent Deadline: July 23 by noon
Sponsor Deadline: Full Application August 29

For those interested, please send an email of intent to the Limited Submissions Team at limitedsubmissions@tufts.edu informing us of an intention to apply. EOI’s received after the deadline will not be considered. The email of intent must include:

1. The name of the solicitation,
2. The name of the Principal Investigator, and any co-PI's,
3. A 2-3 sentence description of the proposed project.

Should the number of interested applicants exceed the number allowed by the funder, an internal selection process will be conducted by the Office of the Vice Provost for Research, and candidates will be notified to submit internal application materials. All candidates will be notified of results. NB: Successful applications must include official notification from the Limited Submissions Team in order to submit. For more information, please see http://viceprovost.tufts.edu/resources/funding/limited-submissions/

PROGRAM PURPOSE:
- The purpose of the National Cancer Institute (NCI)-supported Cancer Prevention Clinical Trials Network (CP-CTNet) Sites opportunity is to provide scientific leadership in development and conduct of early phase cancer prevention clinical trials, as well as in the management and analysis of the data.

PROGRAM REQUIREMENTS:
- Each CP-CTNet Site will consist of a Lead Academic Organization (LAO), which will serve as the research hub and be the UG1 applicant institution, and Affiliated Organizations (AOs) that will collaborate on clinical trials
- The Site must have expertise, skills, and infrastructure for the following (see link below for more detail):
  - Design and conduct early phase cancer prevention clinical trials with designs using ‘omics’ technologies
  - Managing study operations while adhering to rules and regulations relevant to clinical trials
  - Develop 1-3 clinical trials per year, with expected accrual of 10-40 or more participants per year
  - Conduct prevention clinical trials in those at risk for cancers arising in one of at least three different target organs (at least one must be breast, colon, prostate, or lung, and at least one must be something other than these four
  - Obtain mechanistic proof-of-principle data for new agents or approaches directed at novel molecular targets
- Agents to be developed will be announced twice yearly via NCI solicitation

ELIGIBILITY: Sites must have expertise in evaluating multiple types of agents, with emphasis on pharmacologic agents and immuno-preventative vaccines and other immune modulators. PI must have their primary appointment at Tufts University and must be nationally and internationally recognized leaders in clinical trials of cancer preventive agents; PI must not be named as Senior/Key Personnel or Other Significant Contributors on the CP-CTNet DMACC award. Please follow Tufts PI eligibility policies

AWARD INFORMATION: Cooperative Agreement of $600,000 direct costs for year 1 and $1,250,000 in direct costs for years 2-5. All applicants should request a 5-year project period.


NOTE: Program announcement instructions supersede instructions delivered in this document.